ITRI Excels with Eight 2023 R&D 100 Awards, Showcasing Biotechnological Triumph
ITRI's accolades include five net-zero solutions and three novel biomedical technologies, marking a historic win for the institute's biotechnology sector.
- ITRI's accolades include five net-zero solutions and three novel biomedical technologies, marking a historic win for the institute's biotechnology sector.
- "It marks the fifth consecutive year that ITRI's biomedical innovations have earned the prestigious R&D 100 Awards, showcasing the international caliber of Taiwan's biomedical research capabilities," noted ITRI President Edwin Liu.
- All three award-winning technologies have been transferred to Taiwanese companies, reflecting the Institute's commitment to translating research into practical industrial applications.
- Beyond its current applications, iRFA's can potentially be extended to breast and orthopedic tumor ablation and even robotic-assisted surgery.